Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 6.55 USD 0.92% Market Closed
Market Cap: 843.7m USD
Have any thoughts about
Cytek Biosciences Inc?
Write Note

Cytek Biosciences Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cytek Biosciences Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Cytek Biosciences Inc
NASDAQ:CTKB
Accrued Liabilities
$24.2m
CAGR 3-Years
36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Accrued Liabilities
$5.2B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Accrued Liabilities
$2.9B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Accrued Liabilities
$364.6m
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Accrued Liabilities
$573m
CAGR 3-Years
-8%
CAGR 5-Years
5%
CAGR 10-Years
-2%
IQVIA Holdings Inc
NYSE:IQV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cytek Biosciences Inc
Glance View

Market Cap
861.4m USD
Industry
Life Sciences Tools & Services

Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).

CTKB Intrinsic Value
6.58 USD
Undervaluation 1%
Intrinsic Value
Price

See Also

What is Cytek Biosciences Inc's Accrued Liabilities?
Accrued Liabilities
24.2m USD

Based on the financial report for Dec 31, 2023, Cytek Biosciences Inc's Accrued Liabilities amounts to 24.2m USD.

What is Cytek Biosciences Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
36%

Over the last year, the Accrued Liabilities growth was -5%. The average annual Accrued Liabilities growth rates for Cytek Biosciences Inc have been 36% over the past three years .

Back to Top